BridgeBio Pharma (BBIO) Stock Price, News & Analysis

Company Overview

BridgeBio Pharma, Inc. is a biopharmaceutical company focused on discovering, developing and delivering medicines for patients with genetically driven diseases and cancers. Founded in 2015, the company operates through a group of subsidiary biotechnology businesses, each generally focused on a specific disease area or therapeutic program.

BridgeBio’s research and development activities span rare diseases, genetically defined cancers, cardiovascular conditions and other serious disorders. Its portfolio includes therapies designed to address the underlying biological causes of disease, including small-molecule medicines and other targeted treatments. The company’s subsidiary Eidos Therapeutics developed acoramidis, marketed in the United States as Attruby, which received U.S. Food and Drug Administration approval for adults with cardiomyopathy caused by transthyretin-mediated amyloidosis.

BridgeBio supports research, clinical development and commercialization activities through its subsidiaries and collaborators, with clinical programs and business operations serving patients and healthcare markets in the United States and other international geographies. The company is led by founder and Chief Executive Officer Neil Kumar, who has overseen its strategy of building and advancing multiple precision-medicine companies.

Key Stats

• Today's Range: $71.98 to $74.11
• 50-Day Range: $72.44 to $90.17
• 52-Week Range: $48.78 to $93.42
• Volume: 1.77 million shs
• Average Volume: 1.91 million shs
• Market Capitalization: $14.16 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $102.61
• Consensus Rating: Moderate Buy

BridgeBio Pharma Stock Analysis - MarketRank™

BridgeBio Pharma scored higher than 69% of companies evaluated by MarketBeat, and ranked 252nd out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

BridgeBio Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on no strong buy ratings, 20 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

BridgeBio Pharma has a consensus price target of $102.61, representing about 41.6% upside from its current price of $72.44.

Amount of Analyst Coverage

BridgeBio Pharma has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BridgeBio Pharma are expected to grow in the coming year, from ($2.64) to ($0.36) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BridgeBio Pharma is -20.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BridgeBio Pharma is -20.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.03% of the float of BridgeBio Pharma has been sold short.

Short Interest Ratio / Days to Cover

BridgeBio Pharma has a short interest ratio ("days to cover") of 11.18, which indicates bearish sentiment.

Change versus previous month

Short interest in BridgeBio Pharma has recently decreased by 6.34%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BridgeBio Pharma does not currently pay a dividend.

Dividend Growth

BridgeBio Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.36

News Sentiment

BridgeBio Pharma has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for BridgeBio Pharma this week, compared to 10 articles on an average week.

Search Interest

Only 4 people have searched for BBIO on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.

MarketBeat Follows

5 people have added BridgeBio Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 1.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, BridgeBio Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,591,000.00 in company stock.

Percentage Held by Insiders

14.23% of the stock of BridgeBio Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

99.85% of the stock of BridgeBio Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 9/12/2026
• Morgan Stanley 24th Annual Global Healthcare Conference: 9/15/2026
• Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum: 9/23/2026
• Next Earnings (Estimated): 10/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BBIO
• CIK: 1743881
• Web: bridgebio.com
• Phone: (650) 391-9740
• Fax: N/A
• Employees: 839
• Year Founded: 2014

Price Target and Rating

• Average Price Target for BridgeBio Pharma: $102.61
• High Price Target: $120.00
• Low Price Target: $81.00
• Potential Upside/Downside: +41.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 23 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.57)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$724.93 million
• Net Margins: -97.03%
• Pretax Margin: -98.68%
• Return on Equity: N/A
• Return on Assets: -61.19%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.23
• Quick Ratio: 1.17

Sales & Book Value

• Annual Sales: $713.07 million
• Price / Sales: 19.86
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($10.77) per share
• Price / Book: -6.73

Miscellaneous

• Outstanding Shares: 195,487,000
• Free Float: 167,669,000
• Market Cap: $14.16 billion
• Optionable: Optionable
• Beta: 0.97